Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03948867
Other study ID # SPHERE
Secondary ID
Status Enrolling by invitation
Phase Phase 2
First received
Last updated
Start date April 24, 2019
Est. completion date December 31, 2025

Study information

Verified date July 2023
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will 1) Evaluate the prevalence of elevated (conditional or abnormal) transcranial Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia (SCA) living in Tanzania; 2) Obtain longitudinal data on TCD velocities in this population; and 3) Measure the effects of hydroxyurea therapy on TCD velocities and associated primary stroke risk.


Description:

Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE) is a single-center prospective phase 2 pilot study. It will enroll a convenience sample of children with SCA, obtain cross-sectional baseline data at enrolment, and follow them as a prospective cohort for a period of 24 months. The cohort will be divided into two arms based on the initial screening TCD result: 1) those who have a normal (less than 170 cm/sec time averaged mean velocity (TAMV)) initial screening TCD and will be an observation/control cohort; and 2) those who have an elevated initial screening TCD (either conditional (170-199 cm/sec) or abnormal (greater than or equal to 200 cm/sec) TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule. Those who are found to have a normal TCD at enrolment and are part of the observation/control cohort will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant can begin study treatment, but will not be included in the primary endpoint analysis. The primary hypothesis is after 12 months of hydroxyurea therapy, children with conditional TCD velocities will achieve a mean decrease of >15cm/sec from their baseline TCD TAMV.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 202
Est. completion date December 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 2 Years to 16 Years
Eligibility Inclusion Criteria: - Willingness to sign informed consent - Willingness to follow all study procedures - Available for study visits for the duration of the study and no plans to move away from study center. - Confirmed diagnosis of Sickle Cell Anemia (SCA) by haemoglobin electrophoresis. - Able to take oral medication and follow hydroxyurea treatment schedule. Exclusion Criteria: There are no permanent exclusion criteria for participants to enroll in the screening TCD portion of SPHERE. Temporary, time-limited exclusion criteria for the screening TCD portion include the following: - Febrile illness within the past two weeks. (Temporary Exclusion) - Hospitalized within the past two weeks. (Temporary Exclusion) - Transfusion within the past two weeks. (Temporary Exclusion) Patients who enroll in the screening portion, have a conditional or abnormal TCD, and are eligible to start hydroxyurea will be excluded from receiving study treatment if they meet any of the following criteria: - Abnormal pre-enrolment laboratory values (Temporary Exclusion) - Known medical condition making participation ill-advised. - Known allergic reactions to components of hydroxyurea. - Previous history of stroke. - Currently pregnant or lactating.

Study Design


Intervention

Drug:
Hydroxyurea
Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
Diagnostic Test:
Elevated Arm TCD Examination
TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months.
Normal Arm TCD Examination
TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).

Locations

Country Name City State
Tanzania Bugando Medical Centre Mwanza
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio

Sponsors (3)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati Bugando Medical Centre, The American Society of Hematology

Countries where clinical trial is conducted

United States,  Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of Elevated TCD Determine the prevalence of elevated (conditional or abnormal) transcranial Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia (SCA) living in Tanzania Baseline
Primary Change in Primary Stroke Risk Transcranial Doppler ultrasound (TCD) will be used to measure the change in the TAMV of arterial blood flow in the 4 major intracranial arteries bilaterally from study enrollment to 12 months after study enrollment. Up to 12 Months at Month 12
Secondary Laboratory and Clinical Correlates Identify laboratory and clinical correlates of elevated TCD velocities such as age, haemoglobin concentration, foetal haemoglobin, oxygen saturation, splenomegaly, history of acute chest syndrome, and previous malaria infection Up to 24 Months
Secondary Change in Hemoglobin Concentration For those receiving hydroxyurea, the change in hemoglobin between baseline hemoglobin and follow up hemoglobin when a participant has reached maximum tolerated dose of hydroxyurea. 6 Months
Secondary Effect of Splenomegaly and Malaria Infections Incidence of splenomegaly and malaria infection with rapid or laboratory malaria testing will be performed for any child presenting with fever. Incidence will be reported in the number of cases per 100 patient years. Abdominal ultrasound with splenic volume will be performed annually for all study participants. Quantify the degree of hypersplenism or autoinfarction and any association with malaria complications of SCA will be analyzed. Up to 24 Months
Secondary Prevalence of Co-inherited G6PD and Alpha Thalassemia DNA will be collected at baseline to determine the prevalence of co-inherited hematologic diseases such as G6PD and alpha thalassemia. One time at Baseline
Secondary Hydroxyurea Area Under the Curve (AUC) For those receiving hydroxyurea, the AUC will be assessed after the patient has reached MTD. One time at 24 Months (Study Exit)
Secondary Single Nucleotide Polymorphisms Associated with Change in Percent Hemoglobin F on Hydroxyurea For those receiving hydroxyurea, we will identify single nucleotide polymorphisms that are associated with a greater change in hemoglobin F percent in response to hydroyxurea therapy. One Time at 24 Months (Study Exit)
See also
  Status Clinical Trial Phase
Recruiting NCT06387758 - Low Systemic/High Local Exercise Load in Peds SCD N/A
Completed NCT04579926 - PINPOINT: Gaming Technology for SCD Pain N/A
Completed NCT03632876 - Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD N/A
Recruiting NCT05285917 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa Phase 3
Completed NCT04301336 - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Phase 2/Phase 3
Completed NCT03176849 - A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Phase 4
Active, not recruiting NCT04750707 - Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II ) Phase 3
Recruiting NCT05018728 - The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia Phase 2
Recruiting NCT04191213 - Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients Phase 2/Phase 3
Completed NCT04844099 - Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia Phase 3
Completed NCT04800809 - The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria